Evidence map›Paper›PMID 41766859›Full record

ArticleFrontiers in immunology2026

Carnosine protects human microglia against Aβ oligomers through a multimodal mechanism of action: inhibition of oxidative stress, rescue of cellular energy status, and enhancement of phagocytosis.

Anna Privitera, Vincenzo Cardaci, Matthew C Zupan, Lucia Di Pietro, Giuseppe Carota, Jay Sibbitts, Renata Mangione, Andrea Graziani, Lucia Buccarello, Francesco Bellia and 10 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anna Privitera *Department of Drug and Health Sciences, University of Catania, Catania, Italy.
Vincenzo Cardaci *CRA Mirabilis, Fondazione Mantovani, Milan, Arconate (MI), Italy.
Matthew C Zupan *Department of Chemistry, University of Kansas, Lawrence, KS, United States.
Lucia Di PietroDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Giuseppe CarotaDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Jay SibbittsDepartment of Chemistry, University of Kansas, Lawrence, KS, United States.
Renata MangioneDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy.
Andrea GrazianiDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy.
Lucia BuccarelloDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy.
Francesco BelliaDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Valentina Di PietroDepartment of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom.
Giuseppe LazzarinoLTA Biotech S.r.l., Catania, Italy.
Susan M LunteDepartment of Chemistry, University of Kansas, Lawrence, KS, United States.
Meredith D HartleyDepartment of Chemistry, University of Kansas, Lawrence, KS, United States.
Filippo CaraciDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Barbara TavazziDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy.
Emiliano MaianiDepartmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy.
Angela M AmoriniDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Giacomo Lazzarino *Departmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy.
Giuseppe Caruso *Departmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Carnosine is an endogenous dipeptide composed by β-alanine and L-histidine widely distributed in excitable tissues like muscles and brain. Carnosine participates in the cellular defenses against oxidative/nitrosative stress through a multimodal mechanism of action, including scavenging of the reactive oxygen and nitrogen species (ROS and RNS) and, in brain cells, the inhibition of amyloid-beta (Aβ) aggregation. Microglia play a central role in the pathophysiology of Alzheimer's disease (AD), maintaining the homeostasis of the brain microenvironment. However, its hyperactivation causes an increased secretion of inflammatory mediators and free radicals, leading to neuroinflammatory phenomena that exacerbate neurodegeneration. In the present work, carnosine was tested for its ability to protect human microglial cells (HMC3) against Aβ oligomers-induced oxidative stress and energy metabolism unbalance. Methods: The effects of carnosine to modulate nitric oxide (NO) and ROS intracellular levels were evaluated by microchip electrophoresis coupled to laser-induced fluorescence (ME-LIF), while additional stress-related parameters and cellular energy metabolism were investigated through high-performance liquid chromatography (HPLC). Results: Pre-treatment with carnosine counteracted the oxidative/nitrosative stress induced by Aβ1-42 oligomers by decreasing the intracellular levels of NO and ROS, and rescuing GSH levels. Carnosine preserved cellular mitochondrial-related energy metabolism, restoring concentrations of high-energy phosphates, nicotinic coenzymes and oxypurines, and normalizing UDP-derivatives homeostasis. Furthermore, carnosine strongly enhanced the phagocytic activity of HMC3 cells. Discussion/Conclusion: These results demonstrate the protective effects of carnosine on human microglial cells against detrimental alterations induced by Aβ oligomers, underlining the multimodal mechanism of action of this dipeptide and supporting its promising potential in the context of AD pathology.

Indexed as

Amyloid beta-PeptidesCarnosineEnergy MetabolismMicrogliaOxidative StressPhagocytosisCell LineHumansNitric OxideReactive Oxygen SpeciesAmyloid beta-PeptidesCarnosineNitric OxideReactive Oxygen SpeciesAlzheimer’s diseasecarnosineenergy metabolismhuman microglianeurodegenerationoxidative stress

Identifiers

PMID41766859
PMCPMC12946148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.